The New Medical Treatment of Metastatic Renal Cell Carcinoma: A Good Debut, A Lot of Open Questions

European Urology

Volumn 54, Issue 2, 2008, Pages 252-255

  Ficarra, Vincenzo ^a   Novara, Giacomo ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RISK; DRUG MEGADOSE; EDITORIAL; HUMAN; KIDNEY CARCINOMA; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; UNSPECIFIED SIDE EFFECT;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS;

EID: 45849153849     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.05.031     Document Type: Editorial

References (26)

1. Yagoda A., Abi-Rached B., and Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22 (1995) 42-60
2. Bukowski R.M. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80 (1997) 1198-1220
3. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
4. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
5. Garcia J.A., and Rini B.I. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 57 (2007) 112-125
6. Motzer R.J., Bacik J., Murphy B.A., Russo P., and Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
7. Herrmann E., Brinkmann O.A., Bode M.-E., et al. Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon α and 5-fluorouracil. Eur Urol 51 (2007) 1625-1632
8. Ravaud A., Wallerand H., Culine S., et al. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 54 (2008) 315-325
9. Ljungberg B., Hanbury D.C., Kuczyk M.A., et al. Renal cell carcinoma guideline. Eur Urol 51 (2007) 1502-1510
10. National Comprehensive Cancer Network. NCCN clincial practice guidelines in oncology: kidney cancer [v.1.2008]. Available at http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf.
11. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
12. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
13. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
14. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
15. Ficarra V., Galfano A., Novara G., et al. Risk stratification and prognostication of renal cell carcinoma. World J Urol 26 (2008) 115-125
16. Therasse P. Measuring the clinical response. What does it mean?. Eur J Cancer 38 (2002) 1817-1823
17. Patard J.-J., Rioux-Leclercq N., and Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49 (2006) 633-643
18. Margulis V, Wood CG. Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy? Eur Urol. In press. doi:10.1016/j.eururo.2007.12.041.
19. Neill MG, Jewett MA. The once and future role of cytoreductive nephrectomy. Urol Oncol. In press.
20. Roman C.D., Choy H., Nanney L., et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 105 (2002) 43-47
21. Scappaticci F.A., Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91 (2005) 173-180
22. Pantuck A.J., Belldegrun A.S., and Figlin R.A. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?. Clin Cancer Res 13 (2007) 693s-696s
23. Bhojani N., Jeldres C., Patard J.-J., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53 (2008) 917-930
24. Pouessel D., and Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 53 (2008) 376-381
25. Patard J.-J. Looking ahead in renal cell carcinoma: integrating new agents in the armamentarium of the urologist. Eur Urol Suppl 6 (2007) 505-509
26. Eisen T. Adjuvant therapy in renal cell carcinoma: where are we?. Eur Urol Suppl 6 (2007) 492-498